Iron deficinency and heart failure

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-000874-31-SE

Enrollment

Registered

2018-03-23

Start date

2018-06-19

Completion date

Unknown

Last updated

2022-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficinecy and heart failure

Interventions

Trade Name: Inofer Product Name: Inofer Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: To study uptake of ferrosuccinate during Three months in patients with heart failure;Secondary Objective: Not applicable;Primary end point(s):	—

Countries

Sweden

Contacts

Public ContactKurt Boman

Umeå university

kurt.boman@vll.se+460910771113

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026